Fresh analysis indicates that patients who come off blockbuster weight-loss injections like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who halt traditional lifestyle programs.
Findings released in a major health publication demonstrates that while obese individuals often shed a large proportion of their body weight while undergoing treatment, the mass returns at an average rate of 0.8 kg per month once they quit.
"People purchasing these treatments should be informed of the danger of fast weight regain when the medication is stopped," cautioned expert Dr. Susan Jebb.
This pace of regain suggests a reversion to starting mass in about 18 months.
Analyzing Approaches
The research, which reviewed 37 of trials involving thousands of participants, contrasted the results of GLP-1 agonists with conventional dieting.
Scientists note that people who lose weight through lifestyle changes alone typically have a slower creep back—around 0.1 kg a month—after stopping.
Understanding the Rapid Rebound
Nutrition scientists propose the way of the drugs explains the accelerated weight return.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Long-term administration of the hormone levels far above than the body's typical production could lead to the system to produce less of its own natural hormone, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' results in appetite is no longer kept in check, making binge eating far more likely."
A Chronic Condition?
The NHS suggest the jabs for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Many experts contend that, due to the high risk of relapse, the therapy should be considered ongoing.
This view is reinforced by drug manufacturers, who note that the results "emphasize the long-term nature of excess weight," comparing it to managing conditions like hypertension.
User Experiences
Individuals who have stopped the medication describe a powerful return of hunger.
"I experienced a trigger activating and you're instantly starving," said an individual.
This challenge is worsened if patients have not developed sustainable lifestyle or habit changes during therapy.
Widespread Adoption
Survey data suggest that millions of adults in the UK have used weight-loss jabs in the past year, with desire remaining high.
- Adoption is more common among females compared to males.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Ultimately, experts caution that while GLP-1 drugs are effective tools for weight loss, they are not a magic cure and lasting health benefits relies on combined behavioural changes.
